Detail akcie Esperion Therap online

Business Summary: Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Esperion Therapeutics Inc revenues increased 54% to $116.3M. Net loss decreased 10% to $209.2M. Revenues reflect Product sales, net increase of 40% to $78.3M, Collaboration revenue increase of 94% to $38M. Lower net loss reflects Research and development decrease of 28% to $86.1M (expense), Interest Income increase of 83% to $4.4M (income), Other income.